» Articles » PMID: 28523493

The Socio-economic Impact of Work Disability Due to Inflammatory Bowel Disease in Brazil

Overview
Specialty Health Services
Date 2017 May 20
PMID 28523493
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inflammatory bowel disease (IBD) might have economic and social impacts in Brazil, where its prevalence has increased recently. This study aimed to assess disability due to IBD in the Brazilian population and demographic factors potentially associated with absence from work.

Methods: Analysis was performed using the computerized Single System of Social Security Benefits Information, with a cross-check for aid pension and disability retirement, for Crohn's disease (CD) and ulcerative colitis (UC). Additional data were obtained from the platform, including the average values, benefit duration, age, gender and region of the country.

Results: Temporary disability occurred more frequently with UC, whereas permanent disability was more frequent with CD. Temporary disability affected more younger patients with CD than patients with UC. Temporary work absences due to UC and CD were greater in the South, and the lowest absence rates due to CD were noted in the North and Northeast. Absence from work was longer (extending for nearly a year) in patients with CD compared to those with UC. The rates of temporary and permanent disability were greater among women. Permanent disability rates were higher in the South (UC) and Southeast (CD). The value of benefits paid for IBD represented approximately 1% of all social security benefits. The benefits paid for CD were higher than for UC, whereas both tended to decrease from 2010 to 2014.

Conclusions: In Brazil, IBD frequently causes disability for prolonged periods and contributes to early retirement. Reduction trends may reflect improvements in access to health care and medication. Vocational rehabilitation programs may positively impact social security and the patients' quality of life.

Citing Articles

Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.

de Sa Brito Froes R, Andrade A, Faria M, de Souza H, Parra R, Zaltman C Sci Rep. 2024; 14(1):4314.

PMID: 38383742 PMC: 10881489. DOI: 10.1038/s41598-024-54332-1.


Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases.

Parra R, Ferreira S, Machado V, Nigro C, Rocha J, de Almeida Troncon L J Clin Med. 2023; 12(7).

PMID: 37048755 PMC: 10095198. DOI: 10.3390/jcm12072672.


Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.

Sudhakar P, Alsoud D, Wellens J, Verstockt S, Arnauts K, Verstockt B J Crohns Colitis. 2022; 16(8):1306-1320.

PMID: 35150242 PMC: 9426669. DOI: 10.1093/ecco-jcc/jjac027.


Hospitalizations and in-hospital mortality for inflammatory bowel disease in Brazil.

Guedes A, Lorentz A, Rios L, Freitas B, Dias A, Uhlein A World J Gastrointest Pharmacol Ther. 2022; 13(1):1-10.

PMID: 35116179 PMC: 8788161. DOI: 10.4292/wjgpt.v13.i1.1.


Immunological Traits of Patients with Coexistent Inflammatory Bowel Disease and Periodontal Disease: A Systematic Review.

Mello-Neto J, Nunes J, Tadakamadla S, Figueredo C Int J Environ Res Public Health. 2021; 18(17).

PMID: 34501547 PMC: 8430503. DOI: 10.3390/ijerph18178958.


References
1.
Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I . Inflammatory bowel disease: a patient's and caregiver's perspective. Dig Dis Sci. 2009; 54(12):2671-9. DOI: 10.1007/s10620-008-0658-3. View

2.
Siebert U, Wurm J, Matteucci Gothe R, Arvandi M, Vavricka S, von Kanel R . Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study. Inflamm Bowel Dis. 2013; 19(4):847-55. DOI: 10.1097/MIB.0b013e31827f278e. View

3.
Rosch M, Leidl R, Thomas S, von Tirpitz C, Reinshagen M, Adler G . [Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital]. Med Klin (Munich). 2002; 97(3):128-36. DOI: 10.1007/s00063-002-1136-x. View

4.
Bodger K, Yen L, Szende A, Sharma G, Chen Y, McDermott J . Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: a chart review analysis. Eur J Gastroenterol Hepatol. 2013; 26(2):213-21. DOI: 10.1097/01.meg.0000435545.49133.cd. View

5.
Kappelman M, Rifas-Shiman S, Porter C, Ollendorf D, Sandler R, Galanko J . Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135(6):1907-13. PMC: 2613430. DOI: 10.1053/j.gastro.2008.09.012. View